Analysts expect Bristol-Myers Squibb to report revenues of $22.56 billion in fiscal 2018, which will be a rise of 8.58% YoY. The company is also expected to report revenues of $23.83 billion in fiscal 2019, which is a rise of 5.65% YoY. Analysts expect Bristol-Myers Squibb’s fiscal 2020 revenues to be $24.94 billion, which will be a rise of 4.66% YoY.
Analysts project Bristol-Myers Squibb’s revenues to be close to $5.98 billion in the fourth quarter, which will be a rise of 9.76% YoY.
In the third quarter, Bristol-Myers Squibb reported revenues of $5.69 billion, which is a rise of 8.4% YoY on a reported basis and 10% on a constant currency basis. The company missed the consensus revenue estimate by $30 million. Bristol-Myers Squibb reported revenues of $3.23 billion from the US market in the third quarter, which is a rise of 13% YoY.
According to Bristol-Myers Squibb’s third-quarter earnings conference call, the performance was mainly due to solid demand trends and the favorable market share growth trajectory for Opdivo and Eliquis. The company managed to maintain its leadership position in second-line non-small cell lung cancer indication despite stiff competition.
In the first nine months of 2018, Bristol-Myers Squibb reported revenues of $16.59 billion, which is a rise of 8% YoY. The company reported revenues of $9.24 billion from the US market, which is a rise of 9% YoY.
Next, we’ll discuss Bristol-Myers Squibb’s earnings projections.